Immunohistochemistry for caveolin-1 and activated components of the AKT/mTOR pathway in clinically confined RCC. Caveolin-1 staining was comparable to that previously described (Campbell et al ...

The main cell components (protein degradation, cell cycle, mitochondria, PI3K–AKT–mTOR pathway and inflammation) and the main Parkinson's disease-associated proteins (parkin, PTEN induced ...

By measuring the number and variety of phosphate tags on proteins controlled by Akt in the tissue samples, the researchers could get a sense of the overall activity of the Akt-mTOR pathway.

KEY POINTSThe PI3K/AKT/mTOR pathway is an established oncogenic driver in a variety of tumor types.Inhibitors of this pathway are already in clinical testing, ... Tuberous sclerosis complex (TSC) is a ...

In response to growth factors that stimulate the class I phosphatidylinositol 3-kinase–AKT pathway, or other nutrient-related signals (e.g., leucine), mTORC1 negatively regulates a complex ...

Treating the genetically engineered mice with rapamycin, a drug that targets mTOR, not only prevented excessive protein production in mice with a condition like Parkinson's disease, but also eased ...

Approximately half of patients (51%) presented with stage IIA disease. More than 97% of the patients (182) were treated with either a fluoropyrimidine, platinum agent, or taxane. Of these 182 patients ...

Another promising finding of the study was that implanting the artificially-produced neurons in a rodent model with Parkinson's disease led to improvement of the rodent's locomotive impairment.